These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2903851)

  • 1. Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer.
    Gusterson BA; Machin LG; Gullick WJ; Gibbs NM; Powles TJ; Price P; McKinna A; Harrison S
    Int J Cancer; 1988 Dec; 42(6):842-5. PubMed ID: 2903851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma.
    Somerville JE; Clarke LA; Biggart JD
    J Clin Pathol; 1992 Jan; 45(1):16-20. PubMed ID: 1346789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of c-erbB-2 in in situ and in adjacent invasive ductal adenocarcinomas of the female breast.
    Maguire HC; Hellman ME; Greene MI; Yeh I
    Pathobiology; 1992; 60(3):117-21. PubMed ID: 1352687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.
    van de Vijver MJ; Peterse JL; Mooi WJ; Wisman P; Lomans J; Dalesio O; Nusse R
    N Engl J Med; 1988 Nov; 319(19):1239-45. PubMed ID: 2903446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?
    Barnes DM; Bartkova J; Camplejohn RS; Gullick WJ; Smith PJ; Millis RR
    Eur J Cancer; 1992; 28(2-3):644-8. PubMed ID: 1350456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-erbB-2 oncogene in breast cancer: the right target or a decoy?
    Anderson TJ
    Hum Pathol; 1992 Sep; 23(9):971-3. PubMed ID: 1355463
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma--a detailed morphological analysis.
    Ramachandra S; Machin L; Ashley S; Monaghan P; Gusterson BA
    J Pathol; 1990 May; 161(1):7-14. PubMed ID: 1973459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia.
    Porter PL; Garcia R; Moe R; Corwin DJ; Gown AM
    Cancer; 1991 Jul; 68(2):331-4. PubMed ID: 1676930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of c-erbB3 protein in primary breast carcinomas.
    Naidu R; Yadav M; Nair S; Kutty MK
    Br J Cancer; 1998 Nov; 78(10):1385-90. PubMed ID: 9823984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-erbB-2 expression in different histological types of invasive breast carcinoma.
    Soomro S; Shousha S; Taylor P; Shepard HM; Feldmann M
    J Clin Pathol; 1991 Mar; 44(3):211-4. PubMed ID: 1672872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast.
    Lodato RF; Maguire HC; Greene MI; Weiner DB; LiVolsi VA
    Mod Pathol; 1990 Jul; 3(4):449-54. PubMed ID: 2170971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of epithelial abnormalities that resemble human breast lesions by the expression of the neu/erbB-2 oncogene in reconstituted mouse mammary gland.
    Bradbury JM; Arno J; Edwards PA
    Oncogene; 1993 Jun; 8(6):1551-8. PubMed ID: 8099220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-erbB-2 expression in benign and malignant breast disease.
    Gusterson BA; Machin LG; Gullick WJ; Gibbs NM; Powles TJ; Elliott C; Ashley S; Monaghan P; Harrison S
    Br J Cancer; 1988 Oct; 58(4):453-7. PubMed ID: 2849975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ.
    Bartkova J; Barnes DM; Millis RR; Gullick WJ
    Hum Pathol; 1990 Nov; 21(11):1164-7. PubMed ID: 1977679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.
    Wilbur DC; Barrows GH
    Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In situ distribution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-beta-subunit.
    Kommoss F; Colley M; Hart CE; Franklin WA
    Mol Cell Probes; 1990 Feb; 4(1):11-23. PubMed ID: 1969111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer.
    Iglehart JD; Kerns BJ; Huper G; Marks JR
    Breast Cancer Res Treat; 1995 Jun; 34(3):253-63. PubMed ID: 7579490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma.
    Tavassoli M; Quirke P; Farzaneh F; Lock NJ; Mayne LV; Kirkham N
    Br J Cancer; 1989 Oct; 60(4):505-10. PubMed ID: 2572268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK; Tjan S; Parkes RK; O'Malley FP
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.